Fig. 3

Tinostamustine increases the effects of radiotherapy in glioma models in vitro (part II). a Table summarizing subG1 cell percentage measured with propidium iodide (PI) by using Tali™ instrument (Thermo Fisher Scientifics, Carlsbad, CA, USA) in U87MG, U251, A172, and T98G treated with RT with or without TINO. b Western blot performed on Bcl2 and Bax expression performed in A172 cells treated with RT (0–6 Gy) with or without TINO 3.5 μM. c Caspase 3 activity measured in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with or without TINO. d Annexin V/PI positive apoptotic cells performed by using Tali™ Apoptosis Kit - Annexin V Alexa Fluor™ 488 & Propidium Iodide. e Clonogenic assay performed with AT101 (Gossypol, 10.0 μM), Bcl2 inhibitor in U87MG, U251, A172, and T98G. f Table summarizing DRE values calculated in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with or without 10.0 μM AT101. g Table summarizing DRE values calculated in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with or without 10.0 μM AT101 and TINO 3.5 μM (triple combination). Single results are representative of three different experiments performed in triplicate